WeightWatchers shifts to value-based care with GLP-1 strategy
WeightWatchers (WW) recently completed a broader financial reorganization, realigning leadership with a sharper focus on clinical innovation and women’s health, including menopause support. The reorganization includes appointing a chief medical officer to lead a more integrated, medically informed approach.
WW’s reorganization bankruptcy was driven by mounting debt and pressure from newer weight-loss therapy products, namely GLP-1 drugs like Ozempic and Wegovy. It was also impacted by a shifting landscape where traditional …
WeightWatchers shifts to value-based care with GLP-1 strategy





![Why physicians must lead the design of artificial intelligence in health care [PODCAST]](https://kevinmd.com/wp-content/uploads/156891f3-d875-411e-9a3e-c50a13997d53-190x100.jpeg)





![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)



![Why weight regain is a predictable biological response after stopping GLP-1s [PODCAST]](https://kevinmd.com/wp-content/uploads/662faf85-c18d-47d3-8970-8f0e4231882f-190x100.jpeg)

